DESPUES DE 18 AÑOS CON SOLO TOPOTECAN CON FULL APPROVAL EN EEUU COMO TREATMENT 2a LÍNE SCLC-ES ... LA USFDA ACABA DE APROBAR AL TARLATAMAB CON FULL APPROVAL ... POR LO QUE ES YA EL NEW TREATMENT STÁNDARD EN EEUU . TIENE APROBACIÓNES ACELERADAS EN CANADA , UK, COREA ... Y EN DÍAS PODRÍA ALCANZAR LA APROBACIÓN TAMBIÉN EN CHINA QUE EN JULIO 2025, LA NMPA ACEPTÓ LA SOLICITUD DE REGISTRO (NDA) PARA TARLA OTORGÁNDOLE ADEMAS LA REVISIÓN PRIORITARIA . LA EMA TAMBIÉN LO ESTÁ YA EVALUANDO .
30 noviembre 2007
Yondelis en la lista de aprobaciones de Thomson Scientific Publishes , publicada hoy .
The first of two potential treatments for cancer on the list of notabledrugs gaining approval this quarter is Yondelis, developed by PharmaMar forpatients who have not responded to previous regimens in their treatment ofsoft tissue sarcoma. Yondelis is the first approved product from PharmaMar, aSpanish biotech specializing in cancer drugs derived from marine organisms andhas Orphan Drug status in both the EU and U.S., securing extended protectionagainst generic competition.
Aplidin un nuevo agente contra el cáncer marina muy particular, con un retraso en neuromusculares toxicidad con prometedora actividad antitumoral.
Revista Current Pharmaceutical Design de Noviembre 2007 .
Novel Marine-Derived Anti-Cancer Agents.
Aplidine: A Paradigm of how to Handle the Activity and Toxicity of a Novel Marine Anticancer Poison.
Author: Adrian, Thomas E.1
Source: Current Pharmaceutical Design, Volume 13, Number 33, November 2007 , pp. 3417-3426(10)
Publisher: Bentham Science Publishers
Novel Marine-Derived Anti-Cancer Agents.
Aplidine: A Paradigm of how to Handle the Activity and Toxicity of a Novel Marine Anticancer Poison.
Author: Adrian, Thomas E.1
Source: Current Pharmaceutical Design, Volume 13, Number 33, November 2007 , pp. 3417-3426(10)
Publisher: Bentham Science Publishers
Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled
Yondelis en la Revista Cell Proliferation del mes de Diciembre 2007 :
Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach
Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach